Zika Virus Vaccine Candidate from Japan
mRNA-based or DNA vaccine platform for Zika flavivirus prevention, in clinical stages. Fits HTS 3002.49.0050 as other virus culture-derived prophylactic product via biotech processes.
Duty Rate — Japan → United States
0%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Classify as gene therapy if applicable; special USDA permits for vectors
• Document trial phase and IRB approval; frozen shipment standard